Showing results (71-80 of 97) with videos related to
Sort By:
Pageof 10
Journal of Hepatology|April 22, 2015
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agentXavier Forns, Stuart C Gordon, Eli Zuckerman, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 16, 2013
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRKJürgen K Rockstroh, Edwin DeJesus, Jeffrey L Lennox, et al.Annals of Internal Medicine|April 25, 2015
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized TrialStefan Zeuzem, Reem Ghalib, K Rajender Reddy, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 28, 2016
Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world ExperienceSuzanne M Garland, Susanne K Kjaer, Nubia Muñoz, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 17, 2011
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRKJürgen K Rockstroh, Jeffrey L Lennox, Edwin Dejesus, et al.HIV Clinical Trials|August 2, 2012
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRKEdwin DeJesus, Jürgen K Rockstroh, Jeffrey L Lennox, et al.Inflammation|September 5, 2020
Low Plasma Gelsolin Concentrations in Chronic Granulomatous DiseaseJohn Audley, Emily F Gliniewicz, Kol A Zarember, et al.The New England Journal of Medicine|April 1, 2011
Boceprevir for untreated chronic HCV genotype 1 infectionFred Poordad, Jonathan McCone, Bruce R Bacon, et al.Hepatology (Baltimore, Md.)|May 24, 2012
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirinIra M Jacobson, Patrick Marcellin, Stefan Zeuzem, et al.Virology|June 15, 2013
Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysisRichard J O Barnard, Carolyn M McHale, William Newhard, et al.Pageof 10